Background and methods

- **NGR-htNF**: NGR (a 15-mer cyclic peptide) fused to the tumor-homing pentapeptide NGR-

  - **17 cycles** in combination (median: 4; range: 1-6)
  - **18 patients** (46%): 6 cycles
  - **12 patients** (32%): 8 cycles
  - No treatment discontinuations for adverse events (AEs)
  - Grade 1-2 (19 in 19 patients (51%) on NGR-htNF infusion
  - 4 patients (2%) with 1 cardiac events (echocardiograms and diastolic dysfunction)

  - **Study-emergent AEs (10% of patients)**
    - **Survival**:
      - **Patients**: 57 (57-72)
      - **OS**: 21 (12-32) months
      - **OS at 1 year (95% CI):** 76 (68-85)
      - **OS at 2 years (95% CI):** 57 (50-66)
      - **OS at 5 years**: 43 (39-48)
      - **Median OS (95% CI):** 12 (10-15) months
      - **Median progression-free survival (95% CI):** 6.6 months (range 2.4-9.5 months)
      - **Overall survival**
        - **Recurrence-free survival**: 12 (32%)
        - **Progression-free survival**: 6.6 months (range 2.4-9.5 months)
        - **Overall survival**: 12 (32%)